Androgenicity of progestins in hormonal contraceptives and the risk of gestational diabetes mellitus

Diabetes Care

Volumn 30, Issue 5, 2007, Pages 1062-1068

  Hedderson, Monique M ^a,b   Ferrara, Assiamira ^a,b   Williams, Michelle A ^b,c   Holt, Victoria L ^b,d   Weiss, Noel S ^b,d  

^a DIVISION OF RESEARCH   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c SWEDISH MEDICAL CENTER   (United States)

^d Fred Hutchinson Cancer Research Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CONTRACEPTIVE AGENT; ETHINYLESTRADIOL; ETYNODIOL DIACETATE; GESTAGEN; LEVONORGESTREL; METHYLTESTOSTERONE; NORETHISTERONE; NORGESTREL;

ADULT; ARTICLE; CONTRACEPTION; CONTROLLED STUDY; DRUG EFFECT; DRUG FORMULATION; FEMALE; GLUCOSE TOLERANCE; HUMAN; MAJOR CLINICAL STUDY; PREGNANCY; PREGNANCY DIABETES MELLITUS; RISK ASSESSMENT; RISK REDUCTION; TREATMENT OUTCOME; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ADULT; ANDROGENS; BODY MASS INDEX; CALIFORNIA; CONTINENTAL POPULATION GROUPS; CONTRACEPTIVES, ORAL, HORMONAL; DATABASES, FACTUAL; DIABETES, GESTATIONAL; ETHINYL ESTRADIOL; ETHNIC GROUPS; FEMALE; HUMANS; ODDS RATIO; PREGNANCY; RISK FACTORS;

EID: 34247607223     PISSN: 01495992     EISSN: 01495992     Source Type: Journal    
DOI: 10.2337/dc06-2227     Document Type: Article

References (33)

1. Buchanan TA, Xiang AH: Gestational diabetes mellitus. J Clin Invest 115:485-491, 2005
2. American Diabetes Association: Gestational diabetes mellitus (Position Statement). Diabetes Care 21 (Suppl. 1):S60-S61, 1998
3. Petitti DB: Clinical practice: combination estrogen-progestin oral contraceptives. N Engl J Med 349:1443-1450, 2003
4. Kay CR: Progestogens and arterial disease: evidence from the Royal College of General Practitioners' Study. Am J Obstet Gynecol 142:762-765, 1982
5. Darney PD: The androgenicity of progestins. Am J Med 98 (Suppl. 1A):104S-110S, 1995
6. Boden G: Fuel metabolism in pregnancy and in gestational diabetes mellitus. Obstet Gynecol Clin North Am 23:1-10, 1996
7. Godsland IF, Crook D, Simpson R, Proudler T, Felton C, Lees B, Anyaoku V, Devenport M, Wynn V: The effects of different formulations of oral contraceptive agents on lipid and carbohydrate metabolism. N Engl J Med 323:1375-1381, 1990
8. Godsland IF, Walton C, Felton C, Proudler A, Patel A, Wynn V: Insulin resistance, secretion, and metabolism in users of oral contraceptives. J Clin Endocrinol Metab 74:64-70, 1992
9. Perlman JA, Russell-Briefel R, Ezzati T, Lieberknecht G: Oral glucose tolerance and the potency of contraceptive progestins. J Chronic Dis 38:857-864, 1985
10. Wynn V, Godsland I: Effects of oral contraceptives on carbohydrate metabolism. J Reprod Med 31:892-897, 1986
11. Bowes WAJ, Katta LR, Droegemueller W, Bright TG: Triphasic Randomized Clinical Trial: comparison of effects on carbohydrate metabolism. Am J Obstet Gynecol 161:1402-1407, 1989
12. van d V, Kloosterboer HJ, Haspels AA: Effect of seven low-dose combined oral contraceptive preparations on carbohydrate metabolism. Am J Obstet Gynecol 156:918-922, 1987
13. Luyckx AS, Gaspard UJ, Romus MA, Grigorescu F, De Meyts P, Lefebvre PJ: Carbohydrate metabolism in women who used oral contraceptives containing levonorgestrel or desogestrel: a 6-month prospective study. Fertil Steril 45:635-642, 1986
14. Krieger N: Overcoming the absence of socioeconomic data in medical records: validation and application of a census-based methodology. Am J Public Health 82:703-710, 1992
15. American Diabetes Association: Gestational diabetes mellitus. Diabetes Care 23 (Suppl. 1):S77-S79, 2000
16. Ferrara A, Kahn HS, Quesenberry C, Riley C, Hedderson MM: An increase in the incidence of gestational diabetes mellitus: northern California, 1991-2000. Obstet Gynecol 103:526-533, 2004
17. Ferrara A, Weiss NS, Hedderson MM, Quesenberry CP, Jr, Selby JV, Ergas IJ, Peng T, Escobar GJ, Pettitt DJ, Sacks DA: Pregnancy plasma glucose levels exceeding the American Diabetes Association thresholds, but below the National Diabetes Data Group thresholds for gestational diabetes mellitus, are related to the risk of neonatal macrosomia, hypoglycaemia and hyperbilirubinaemia. Diabetologia 50:298-306, 2006
18. Greer JB, Modugno F, Allen GO, Ness RB: Androgenic progestins in oral contraceptives and the risk of epithelial ovarian cancer. Obstet Gynecol 105:731-740, 2005
19. Dickey RP: Managing Contraceptive Pill Patients. Durant, Oklahoma, Creative Informatics, 1984
20. Tuask M, de Visser J: International Encyclopedia of Pharmacology and Therapeutics. Elmsford, NY, Pergamon Press, 1972
21. Fahmy K, Abdel-Razik M, Shaaraway M, al-Kholy G, Saad S, Wagdi A, al-Azzony M: Effect of long-acting progestagen-only injectable contraceptives on carbohydrate metabolism and its hormonal profile. Contraception 44:419-430, 1991
22. Konje JC, Otolorin EO, Ladipo OA: The effect of continuous subdermal levonorgestrel (Norplant) on carbohydrate metabolism. Am J Obstet Gynecol 166:15-19, 1992
23. Leahy JL, Bonner-Weir S, Weir GC: Beta-cell dysfunction induced by chronic hyperglycemia: current ideas on mechanism of impaired glucose-induced insulin secretion. Diabetes Care 15:442- 455, 1992
24. Wynn V, Adams PW, Godsland I, Melrose J, Niththyananthan R, Oakley NW, Seed M: Comparison of effects of different combined oral-contraceptive formulations on carbohydrate and lipid metabolism. Lancet 1:1045-1049, 1979
25. Spellacy WN, Buhi WC, Birk SA: Carbohydrate and lipid metabolic studies before and after one year of treatment with ethynodiol diacetate in "women." Fertil Steril 27:900-904, 1976
26. Spellacy WN, Buhi WC, Birk SA: Prospective studies of carbohydrate metabolism in "normal" women using norgestrel for eighteen months. Fertil Steril 35:167-171, 1981
27. Wynn V, Doar JW: Some effects of oral contraceptives on carbohydrate metabolism. Lancet 2:761-765, 1969
28. Spellacy WN: Carbohydrate metabolism during treatment with estrogen, progestogen, and low-dose oral contraceptives. Am J Obstet Gynecol 142:732-734, 1982
29. Wynn V: Effect of duration of low-dose oral contraceptive administration on carbohydrate metabolism. Am J Obstet Gynecol 142:739-746, 1982
30. Lo JC, Feigenbaum SL, Escobar GJ, Yang J, Crites YM, Ferrara A: Increased prevalence of gestational diabetes mellitus among women with diagnosed polycystic ovary syndrome: a population-based study. Diabetes Care 29:1915-1917, 2006
31. Mikola M, Hiilesmaa V, Halttunen M, Suhonen L, Tiitinen A: Obstetric outcome in women with polycystic ovarian syndrome. Hum Reprod 16:226-229, 2001
32. Mastorakos G, Koliopoulos C, Deligeoroglou E, Diamanti-Kandarakis E, Creatsas G: Effects of two forms of combined oral contraceptives on carbohydrate metabolism in adolescents with polycystic ovary syndrome. Fertil Steril 85:420-427, 2006
33. Chasan-Taber L, Willett WC, Stampfer MJ, Hunter DJ, Colditz GA, Spiegelman D, Manson JE: A prospective study of oral contraceptives and NIDDM among U.S. women. Diabetes Care 20:330-335, 1997